Pulmonary Alveolar Proteinosis: Is the Focus in Treatment Shifted From ‘Physical’ to ‘Pharmacological’?

Study limitation reported by the research below: “Pharmacological therapies for PAP (e.g., GM-CSF supplementation) remain variably available and are not yet universally approved across all regions, which may affect generalizability of recommendations.”